๐Ÿ”ฌDeep Research

JBIO โ€” Jade Biosciences Inc ยท catalysts, narrative & risks

ยท11 sourcesJBIO forecast โ†’

Jade Biosciences Inc. (Nasdaq: JBIO) โ€” Point-in-Time Assessment (as of 2026-10-30)

Company Snapshot

Jade Biosciences is a clinical-stage biotechnology company developing monoclonal antibody therapies targeting the "upstream drivers" of autoimmune diseases, with a goal of patient-friendly, infrequent subcutaneous dosing [10]. Its lead programs are JADE101 (anti-APRIL, in IgA nephropathy/IgAN), JADE201 (anti-BAFF-R), and JADE301 (anti-IFN-ฮฒ, in dermatomyositis) [5], [9].


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’